CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
Inflation is outrunning growth, squeezing consumers and raising fear of a summer slowdown as high rates and sticky prices test spending and markets today now.
TIME's editorial director Emma Barker unpacks the 2026 100 Most Influential Companies list, spotlighting trends, AI impact, surprises, and leadership shifts.
From dire wolves to new species targets, scientists at Colossal Biosciences are using gene editing to revive extinction and reshape biodiversity as we know it.
R.J. Hottovy, Head of Analytical Research at Placer.ai, breaks down restaurant trends, pricing power, and which chains are winning this earnings season.
William Shatner and LifeWave CEO David Schmidt share lessons from his “world’s oldest intern” experience and offer advice for young professionals starting out.
